Skip to main content
. 2015 May 29;29(9):1152–1155. doi: 10.1038/eye.2015.87

Figure 1.

Figure 1

Representative OCT images of a study patient. (a) Before initiation of anti-VEGF therapy with subretinal and intraretinal cystic fluid. (b) Stable resolution of fluid on 4-week ranibizumab treatment regimen, with return of fluid upon attempts to extend treatment interval beyond 4 weeks. (c) Maintenance of fluid resolution on 8-week aflibercept treatment regimen.